欧美变态杂交xxxx,老色批影院,亚洲一级黄色片

Pfizer Full Year 2025 Financial Report Pfizer Financial statements Pfizer’s 2025 financial results show a 2% decline in revenue, driven by lower COVID-19 product sales. Non-COVID products and a strong R&D pipeline drive growth. The company projects steady performance with key catalysts in 2026.
Novo Nordisk Full Year 2025 Financial Report Novo Nordisk Financial statements Novo Nordisk's 2025 report highlights strong revenue growth driven by Wegovy? and Ozempic?, despite challenges in profit margins and rising costs. The company focuses on R&D, sustainability, and managing risks like competition and regulatory pressures.
Daiichi Sankyo Full Year 2025 Financial Report Financial statements Daiichi Sankyo Daiichi Sankyo's FY2025 Q3 report highlights $4.4 billion in sales for Enhertu (DS-8201) and significant growth in its ADC portfolio. With groundbreaking treatments and strong pipeline advancements, the company is reshaping the oncology landscape.
Novartis Full Year 2025 Financial Report Financial statements Novartis Novartis' 2025 financial results show strong growth, driven by innovations like Kisqali, Pluvicto, and Leqvio. With a strong pipeline and key market expansions, the company is well-positioned for future growth despite patent challenges.
Roche Full Year 2025 Financial Report Financial statements Roche Roche's 2025 financial results show a 7% sales growth, driven by innovative drugs and diagnostics. Core operating profit rose 13%, with strong performance across key markets. The company remains optimistic for 2026, focusing on sustainable growth.
Lonza Full Year 2025 Financial Report Lonza Financial statements Lonza reported $7B in revenue for 2025, with its CDMO business driving 70% of growth. Strategic shifts, expanded capacity, and a focus on next-gen therapies like CGT and ADCs position Lonza for continued success in 2026.
Sanofi Full Year 2025 Financial Report Sanofi Financial statements Sanofi's 2025 results show a 9.9% revenue growth to €43.63 billion, driven by strong sales of Dupixent and new product launches. The company also achieved significant R&D breakthroughs, strategic investments, and continued commitment to sustainability.
Global Biopharma Layoffs February 2026 Layoffs Layoff GSK BMS Global Biopharma companies including GSK, IO Biotech, and Bitterroot Bio announce workforce reductions in February 2026 as part of cost-saving and strategic realignments, impacting research, technology, and leadership roles across their operations.
Global Biopharma Layoffs January 2026 Layoffs Layoff Takeda Gilead This article tracks recent biotech and pharma layoffs, including major workforce cuts at Voyager Therapeutics, Intercept Pharmaceuticals, Mythic Therapeutics, Pfizer, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.
Global Biopharma Layoffs December 2025 Layoffs Layoff Pfizer This article tracks recent biotech and pharma layoffs, including major workforce cuts at Voyager Therapeutics, Intercept Pharmaceuticals, Mythic Therapeutics, Pfizer, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.